Boston Scientific Corp
NYSE: BSX
$83.92
+$0.21 (+0.3%)
Closing Price on September 20, 2024
BSX Articles
It seems that all of a sudden corporations are deciding to do the right thing by getting rid CEO’s that have put the companies and shareholders in untenable positions. We called CEO James Donald of...
Published:
Last Updated:
2007 has been a volatile year in the stock market, but there are many key technology CEO’s who just aren’t making a passing grade. a673b.bigscoots-temp.com has issued a brief list of some recognized CEO’s...
Published:
Last Updated:
For Boston Scientific (BSX) the news gets worse every day. The FDA says it will set up new guidelines for testing stents, which is one of BSX’s largest businesses. According to The Wall Street...
Published:
According to Reuters, Citigroup (C) will take $49 billion of SIVs onto its balance sheet. Reuters writes that Nissan and Chrysler may begin to partner in building new cars Reuters reports that Acer...
Published:
Not many stocks are likely to double. Even well-run companies like Cisco Systems (NASDAQ:CSCO) are not likely to move 2x even with great results. The market caps are already too large and the law of...
Published:
Last Updated:
James Tobin, the CEO of Boston Scientific (NYSE:BSX) is likely to find himself in front of the shareholder firing squad in 2008. In early 2004 this stock was above $40 and had enjoyed an incredible...
Published:
Last Updated:
Abbott Labs (ABT) which just launched a new stent product, Xience V, has laid off 1,200 people because of slowness in the stent market. Stranger than fiction. According to MarketWatch, Abbott says it...
Published:
Looking around the wreckage of some of the big cap companies it is not hard to find a few CEOs who probably need to go back to business school. Wall St. would like to see them at Harvard so they...
Published:
Abbot Labs (ABT) is trying to get into the stent business. The market has been dominated by Boston Scientific (BSX) and Johnson & Johnson (JNJ). Stents are small mess implants which are designed...
Published:
Boston Scientific (BSX) has been the leader in sales of stents, those little mess tubes that keep arteries open. Recent studies show that the devices are more dangerous than most doctors had...
Published:
It is always interesting seeing which groups and which stocks saw the biggest changes in short interest. This list doesn’t show financials because we’ve already shown that individually. Here...
Published:
Last Updated:
Several studies which showed that stents could cause blood clotting in the heart have done significant damage to the revenue for those products at Boston Scientific (BSX) and Johnson & Johnson...
Published:
According to Reuters, BHP Billiton (BHP) will not sell its petroleum division, as had been rumored, to finance a bid for Rio Tinto (RTP). Reuters writes that most of the Hershey (HSY) was pushed out...
Published:
Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson. It now has long-term debt of almost $8.3 billion. Troubles in its...
Published:
"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up in South Florida. Still, restoring luster to the...
Published: